Medigus Ltd.Find Ratings Reports
MEDIGUS's gross profit margin for the fourth quarter of its fiscal year 2018 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. MEDIGUS is extremely liquid. Currently, the Quick Ratio is 7.94 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 46.59% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY18||Q4 FY17|
|Net Sales ($mil)||0.1||0.15|
|Net Income ($mil)||-0.84||0.02|
|Balance Sheet||Q4 FY18||Q4 FY17|
|Cash & Equiv. ($mil)||10.63||6.33|
|Total Assets ($mil)||11.24||7.21|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q4 FY18||Q4 FY17|
|Gross Profit Margin||41.84||64.29|
|Return on Assets||-58.7||-35.29|
|Return on Equity||-81.66||-46.18|
|Debt||Q4 FY18||Q4 FY17|
|Share Data||Q4 FY18||Q4 FY17|
|Shares outstanding (mil)||3.8||0.96|
|Div / share||0.0||0.0|
|Book value / share||2.13||5.75|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||15749.0||75490.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.06 indicates a significant discount versus the S&P 500 average of 3.44 and a significant discount versus the industry average of 16.26. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, MEDIGUS seems to be trading at a premium to investment alternatives.
|MDGS NM||Peers 55.23||MDGS NM||Peers 46.24|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
MDGS's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
MDGS's P/CF is negative making the measure meaningless.
|MDGS NA||Peers 35.65||MDGS NA||Peers 1.22|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|MDGS 1.06||Peers 16.26||MDGS 56.92||Peers 263.45|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MDGS is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, MDGS is expected to significantly trail its peers on the basis of its earnings growth rate.
|MDGS 19.50||Peers 7.17||MDGS -6.64||Peers 10.14|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MDGS is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
MDGS significantly trails its peers on the basis of sales growth.